ZOSTER EASE: A Phase Ib Shingles Treatment Study

Wintermute Biomedical is conducting a Phase Ib clinical trial (WNTR-VZV-001) to assess the safety and tolerability of Solexan™, a topical treatment for shingles. The double-blind, randomized, placebo-controlled study will enroll up to 30 participants with shingles who will apply Solexan™ or a placebo twice daily for 10 days. The trial's primary endpoints focus on safety, while secondary and exploratory endpoints examine pain reduction and lesion healing. Listen to an overview of the study design and why it matters here.